NO2424557T3 - - Google Patents
Info
- Publication number
- NO2424557T3 NO2424557T3 NO10718379A NO10718379A NO2424557T3 NO 2424557 T3 NO2424557 T3 NO 2424557T3 NO 10718379 A NO10718379 A NO 10718379A NO 10718379 A NO10718379 A NO 10718379A NO 2424557 T3 NO2424557 T3 NO 2424557T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17457509P | 2009-05-01 | 2009-05-01 | |
| US33945810P | 2010-03-04 | 2010-03-04 | |
| PCT/US2010/033345 WO2010127336A1 (en) | 2009-05-01 | 2010-05-03 | Modified compstatin with peptide backbone and c-terminal modifications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2424557T3 true NO2424557T3 (enExample) | 2018-03-24 |
Family
ID=42245589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO10718379A NO2424557T3 (enExample) | 2009-05-01 | 2010-05-03 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8946145B2 (enExample) |
| EP (1) | EP2424557B1 (enExample) |
| JP (2) | JP5882890B2 (enExample) |
| CN (1) | CN102458438A (enExample) |
| AU (1) | AU2010242739B2 (enExample) |
| CA (1) | CA2760839C (enExample) |
| DK (1) | DK2424557T3 (enExample) |
| ES (1) | ES2655389T3 (enExample) |
| HU (1) | HUE035378T2 (enExample) |
| NO (1) | NO2424557T3 (enExample) |
| PL (1) | PL2424557T3 (enExample) |
| PT (1) | PT2424557T (enExample) |
| WO (1) | WO2010127336A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| WO2011106635A1 (en) | 2010-02-25 | 2011-09-01 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
| US20130324482A1 (en) * | 2010-07-09 | 2013-12-05 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of rhinosinusitis and nasal polyposis |
| WO2012040259A2 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| US20140219999A1 (en) | 2011-04-01 | 2014-08-07 | The Trustees Of The University Of Pennsylvania | Treatment of colon cancer using complement inhibitors |
| CN107050422B (zh) * | 2011-05-11 | 2021-11-09 | 阿佩利斯制药公司 | 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途 |
| WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
| WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
| MX379206B (es) | 2011-06-22 | 2025-03-10 | Apellis Pharmaceuticals Inc | Uso de inhibidores del complemento en trastornos crónicos. |
| CN110229216B (zh) * | 2011-09-07 | 2023-06-16 | 宾夕法尼亚州大学理事会 | 具有改善的药代动力学性质的坎普他汀类肽 |
| US9579360B2 (en) * | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| PT3660033T (pt) | 2012-11-15 | 2021-07-06 | Apellis Pharmaceuticals Inc | Análogos de compstatina de longa ação e composições e métodos relacionados |
| US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| JP6710638B2 (ja) | 2013-12-12 | 2020-06-17 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 補体成分ｉＲＮＡ組成物及びその使用方法 |
| WO2015142701A1 (en) | 2014-03-17 | 2015-09-24 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved potency and pharmacokinetic properties |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| RU2770099C2 (ru) | 2015-10-07 | 2022-04-14 | Апеллис Фармасьютикалс, Инк. | Схемы введения |
| FI3985002T3 (fi) | 2017-03-01 | 2025-07-30 | Achillion Pharmaceuticals Inc | Aryyli-, heteroaryyli- ja heterosyklisiä lääkeyhdisteitä sairauksien hoitoon |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| US11040107B2 (en) | 2017-04-07 | 2021-06-22 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| US20190038623A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
| US11866701B2 (en) | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| MA51162A (fr) | 2017-12-15 | 2020-10-21 | Apellis Pharmaceuticals Inc | Schémas posologiques et compositions et procédés associés |
| EP3759120A1 (en) * | 2018-02-27 | 2021-01-06 | Zp Spv 3 K/S | Compstatin analogues and their medical uses |
| JP7423070B2 (ja) | 2018-04-06 | 2024-01-29 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 増加した溶解度および改善された薬物動態特性を有するコンプスタチンアナログ |
| CN112839945A (zh) | 2018-09-06 | 2021-05-25 | 艾其林医药公司 | 补体因子d抑制剂的形态形式 |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| AU2019406830A1 (en) | 2018-12-17 | 2021-07-08 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| EP3941462A4 (en) | 2019-03-22 | 2023-04-05 | Achillion Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES |
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| AU2020369515A1 (en) | 2019-10-22 | 2022-04-21 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| CA3174082A1 (en) | 2020-03-04 | 2021-09-10 | Nihon Medi-Physics Co., Ltd. | Compound and radioactive labeling compound |
| WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| IL297680A (en) | 2020-04-30 | 2022-12-01 | Alnylam Pharmaceuticals Inc | Complement factor b (cfb) irna compositions and methods of use thereof |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022186311A1 (ja) | 2021-03-04 | 2022-09-09 | 日本メジフィジックス株式会社 | 化合物及び放射性標識化合物 |
| JP2024535850A (ja) | 2021-09-17 | 2024-10-02 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法 |
| WO2023048151A1 (ja) * | 2021-09-22 | 2023-03-30 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有する環状ペプチド |
| IL312399A (en) | 2021-10-29 | 2024-06-01 | Alnylam Pharmaceuticals Inc | Complement factor B (CFB) iRNA compositions and methods of using them |
| US20250032652A1 (en) | 2021-11-30 | 2025-01-30 | Nihon Medi-Physics Co., Ltd. | Stabilized radiopharmaceutical composition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2295746A1 (fr) | 1974-12-23 | 1976-07-23 | Francaise Coop Pharma | Nouveaux derives du tryptophane a activite nerveuse centrale renforcee |
| IT1179866B (it) | 1984-12-12 | 1987-09-16 | Rotta Research Lab | Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono |
| US4576750A (en) | 1985-04-22 | 1986-03-18 | Merck & Co., Inc. | Tryptophan derivative |
| US5776970A (en) | 1994-04-28 | 1998-07-07 | Yeda Research And Development Co. Ltd. | Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases |
| AU2203197A (en) | 1996-03-13 | 1997-10-01 | Trustees Of The University Of Pennsylvania, The | Novel peptides which inhibit complement activation |
| US6169057B1 (en) | 1997-09-04 | 2001-01-02 | The Regents Of The University Of California | Use of tryptophan and analogs as plant growth regulators |
| WO1999013899A1 (en) * | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides and peptidomimetics for inhibiting complement activation |
| WO1999052539A1 (en) | 1998-04-10 | 1999-10-21 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| EP2311480B1 (en) * | 2002-09-20 | 2013-06-26 | The Trustees of The University of Pennsylvania | Compstatin analogs with improved activity |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| BRPI0617186A2 (pt) * | 2005-10-08 | 2011-07-19 | Potentia Pharmaceuticals Inc | uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste |
| ES2677619T3 (es) * | 2005-11-28 | 2018-08-03 | The Trustees Of The University Of Pennsylvania | Análogos potentes de la compstatina |
| US8442776B2 (en) | 2007-06-08 | 2013-05-14 | The Trustees Of The University Of Pennsylvania | Structure of compstatin-C3 complex and use for rational drug design |
-
2010
- 2010-05-03 NO NO10718379A patent/NO2424557T3/no unknown
- 2010-05-03 HU HUE10718379A patent/HUE035378T2/en unknown
- 2010-05-03 PT PT107183790T patent/PT2424557T/pt unknown
- 2010-05-03 PL PL10718379T patent/PL2424557T3/pl unknown
- 2010-05-03 AU AU2010242739A patent/AU2010242739B2/en active Active
- 2010-05-03 US US13/318,272 patent/US8946145B2/en active Active
- 2010-05-03 JP JP2012508814A patent/JP5882890B2/ja active Active
- 2010-05-03 CA CA2760839A patent/CA2760839C/en active Active
- 2010-05-03 EP EP10718379.0A patent/EP2424557B1/en active Active
- 2010-05-03 ES ES10718379.0T patent/ES2655389T3/es active Active
- 2010-05-03 WO PCT/US2010/033345 patent/WO2010127336A1/en not_active Ceased
- 2010-05-03 CN CN2010800262930A patent/CN102458438A/zh active Pending
- 2010-05-03 DK DK10718379.0T patent/DK2424557T3/en active
-
2015
- 2015-02-02 US US14/611,742 patent/US9371365B2/en active Active
- 2015-10-06 JP JP2015198674A patent/JP6106731B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9371365B2 (en) | 2016-06-21 |
| PL2424557T3 (pl) | 2018-04-30 |
| US20150203539A1 (en) | 2015-07-23 |
| JP5882890B2 (ja) | 2016-03-09 |
| AU2010242739B2 (en) | 2016-08-25 |
| US20120178694A1 (en) | 2012-07-12 |
| JP2016041711A (ja) | 2016-03-31 |
| US8946145B2 (en) | 2015-02-03 |
| JP2012525443A (ja) | 2012-10-22 |
| WO2010127336A1 (en) | 2010-11-04 |
| CA2760839A1 (en) | 2010-11-04 |
| DK2424557T3 (en) | 2018-01-22 |
| JP6106731B2 (ja) | 2017-04-05 |
| ES2655389T3 (es) | 2018-02-19 |
| EP2424557B1 (en) | 2017-10-25 |
| HUE035378T2 (en) | 2018-05-02 |
| PT2424557T (pt) | 2018-02-05 |
| AU2010242739A1 (en) | 2011-12-08 |
| CA2760839C (en) | 2019-02-12 |
| CN102458438A (zh) | 2012-05-16 |
| EP2424557A1 (en) | 2012-03-07 |